AR (Ab-650) Antibody

Code CSB-PA227367
Size US$297
  • Western blot analysis of extracts from Mouse kindey and brain tissue using Androgen Receptor (Ab-650) Antibody.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Rabbit anti-Homo sapiens (Human) AR Polyclonal antibody
Uniprot No. P10275
Target Names AR
Alternative Names AIS antibody; ANDR_HUMAN antibody; Androgen nuclear receptor variant 2 antibody; Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease) antibody; Androgen receptor antibody; androgen receptor splice variant 4b antibody; AR antibody; AR8 antibody; DHTR antibody; Dihydro testosterone receptor antibody; Dihydrotestosterone receptor (DHTR) antibody; Dihydrotestosterone receptor antibody; HUMARA antibody; HYSP1 antibody; KD antibody; Kennedy disease (KD) antibody; NR3C4 antibody; Nuclear receptor subfamily 3 group C member 4 (NR3C4) antibody; Nuclear receptor subfamily 3 group C member 4 antibody; SBMA antibody; SMAX1 antibody; Spinal and bulbar muscular atrophy (SBMA) antibody; Spinal and bulbar muscular atrophy antibody; Testicular Feminization (TFM) antibody; TFM antibody
Raised in Rabbit
Species Reactivity Human
Immunogen Peptide sequence around aa.648~652 (T-T-S-P-T) derived from Human Androgen Receptor.
Immunogen Species Homo sapiens (Human)
Clonality Polyclonal
Purification Method Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.
Concentration It differs from different batches. Please contact us to confirm it.
Form Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Tested Applications ELISA,WB
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:1000
Protocols ELISA Protocol
Western Blotting(WB) Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Data

Function Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
Gene References into Functions
  1. AR expression heterogeneity is linked to distinct castration/enzalutamide responses in castration-resistant prostate cancer. PMID: 30190514
  2. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features PMID: 29883487
  3. In prostate cancer cells, AR-V7 expression is correlated with drug resistance, as AR-V7 upregulation leads to enhanced proliferation potency of cancer cells, indicating unfavorable prognosis of patients. PMID: 30284554
  4. These findings imply that the deep intronic mutation creating an alternative splice acceptor site resulted in the production of a relatively small amount of wildtype androgen receptor mRNA, leading to partial androgen insensitivity syndrome. PMID: 29396419
  5. AR Germline Mutations and Polymorphisms were associated with Prostate Cancer. PMID: 30139231
  6. GTEE also downregulated the expression of AR and prostate-specific antigen (PSA) in both androgen-responsive and castration-resistant PCa cells. By blocking the SREBP-1/AR axis, GTEE suppressed cell growth and progressive behaviors, as well as activating the caspase-dependent apoptotic pathway in PCa cells PMID: 30301150
  7. Suppressed the expression of androgen receptor. PMID: 29981500
  8. An AR motif of the transactivation domain has been identified that contributes to transcriptional activity by recruiting the C-terminal domain of subunit 1 of the general transcription regulator TFIIF. PMID: 29225078
  9. In LNCaP prostate cancer cells, TSG101 overexpression recruits the androgen receptor (AR) to TSG101-containing cytoplasmic vesicles resulting in reduced AR protein level and AR transactivation activity downregulation. Immunofluorescence microscopy demonstrated that TSG101-decorated cytoplasmic vesicles are associated with late endosomes/lysosomes. PMID: 29859188
  10. Study indicates that both mRNA and protein level of AR increase during prostate cancer (PCa) progression. These levels are even higher in metastatic PCa. Further data suggest that elevation of AR may promote PCa metastasis by induction of EMT and reduction of KAT5. PMID: 30142696
  11. This study aimed to determine the presence and localization of oestrogen receptors (ERs), progesterone receptors (PRs), and androgen receptors (ARs) in both healthy and varicose vein wall cells and their relationship with gender. PMID: 30250632
  12. These findings suggest that CDK11 is involved in the regulation of AR pathway and AR can be a potential novel prognostic marker and therapeutic target for osteosarcoma treatment. PMID: 28262798
  13. We use CPRC prostate cancer model and demonstrate that endothelial cells secrete large amount of CCL5 and induces autophagy by suppressing AR expression in prostate cancer cell lines. Consequently, elevated autophagy accelerates focal adhesions proteins disassembly and promoted prostate cancer invasion. Inhibition of both CCL5/CCR5 signaling and autophagy significantly reduces metastasis in vivo PMID: 30200999
  14. Overexpression of nuclear AR-V7 protein identifies a subset of tumors with remarkably aggressive growth characteristics among clinically and histologically high-risk patients at the time of radical prostatectomy. PMID: 29198908
  15. Study defines AR ligand-binding domain homodimerization as an essential step in the proper functioning of this important transcription factor. Dimerization surface harbours over 40 previously unexplained androgen insensitivity syndromes and prostate cancer-associated point mutations. PMID: 28165461
  16. Loss of AR expression was found in the nucleus of penile cancer cells when compared to normal tissues. Cytoplasmic AR immunostaining was observed in a significant number of these cases and was related with poor prognosis and shorter overall survival. PMID: 30099587
  17. The AR polymorphism is associated with POR risk, patients with repeats greater than 22 show a higher risk. Our data suggest that AR genotype could play a role in natural ovarian aging. PMID: 29886316
  18. In all, these data suggest that Aurora A plays a pivotal role in regulation of Androgen receptor variant 7 expression and represents a new therapeutic target in castrate-resistant prostate cancer. PMID: 28205582
  19. The meta-analysis showed that short CAG and GGN repeats in androgen receptor gene were associated with increased risk of prostate cancer, especially in Caucasians. PMID: 28091563
  20. Knockdown of beta-Klotho produced the opposite effects. In conclusion, beta-Klotho inhibits EMT and plays a tumorsuppressive role in prostate cancer (PCa) , linking FGF/FGFR/beta-Klotho signaling to the regulation of PCa progression. PMID: 29749458
  21. The interaction of AR and SP1 contributes to regulate EPHA3 expression. PMID: 29917167
  22. DHX15 regulates androgen receptor (AR) activity by modulating E3 ligase Siah2-mediated AR ubiquitination independent of its ATPase activity promoting prostate cancer progression. PMID: 28991234
  23. The interaction of Nanog with the AR signaling axis might induce or contribute to Ovarian cancer stem cells regulation. In addition, androgen might promote stemness characteristics in ovarian cancer cells by activating the Nanog promoter PMID: 29716628
  24. a significant subset of endometrial cancers express androgen receptor especially a serous cancers. PMID: 29747687
  25. Letter: eradication of androgen receptor amplification, PSA decline, and clinical improvement with high dose testosterone therapy. PMID: 28040353
  26. The results in this meta-analysis indicated that AR CAG and GGN repeat polymorphisms may be an important pathogenesis of cryptorchidism. PMID: 29044734
  27. the inverse relation observed between bone cell activity and tumor cell AR activity in prostate cancer bone metastasis may be of importance for patient response to AR. PMID: 29670000
  28. Length variations of (CAG)n and (GGC)n polymorphism in the transactivation domain of AR, significantly influence hormonal profile, semen parameters, and sexual functions of asthenospermic subjects by down regulating the expression of AR mediating signaling. PMID: 29083935
  29. Data suggest that somatic mosaicism in AR can cause partial androgen insensitivity syndrome. [CASE REPORT] PMID: 29267169
  30. These results identify HoxB13 as a pivotal upstream regulator of AR-V7-driven transcriptomes that are often cell context-dependent in CRPC, suggesting that HoxB13 may serve as a therapeutic target for AR-V7-driven prostate tumors. PMID: 29844167
  31. TRX1 is an actionable castration-resistant prostate cancer therapeutic target through its protection against AR-induced redox stress. PMID: 29089489
  32. these findings reveal AR-genomic structural rearrangements as important drivers of persistent AR signalling in castration-resistant prostate cancer. PMID: 27897170
  33. AR+ was associated with lower breast cancer mortality in the overall study population ( estrogen receptor-negative). PMID: 28643022
  34. nuclear COBLL1 interacts with AR to enhance complex formation with CDK1 and facilitates AR phosphorylation for genomic binding in castration-resistant prostate cancer model cells. PMID: 29686105
  35. A variety of AR mutants are induced under selective pressures of AR pathway inhibition in castration resistant prostate cancer which remain sensitive to the inhibitor darolutamide. PMID: 28851578
  36. c.3864T>C AR novel mutation is responsible for complete androgen insensitivity syndrome [case report] PMID: 29206494
  37. The Spinal and bulbar muscular atrophy is caused by the expansion of a CAG/glutamine tract in the amino-terminus of the androgen receptor PMID: 29478604
  38. Polysomic AR genes show low methylation levels and high AR protein expression on immunohistochemistry PMID: 29802469
  39. Oral administration of RAD140 substantially inhibited the growth of AR/ER(+) breast cancer patient-derived xenografts (PDX). Activation of AR and suppression of ER pathway, including the ESR1 gene, were seen with RAD140 treatment. PMID: 28974548
  40. The aims of this study was to evaluate if extreme CAG and GGN repeat polymorphisms of the androgen receptors influence body fat mass, its regional distribution, resting metabolic rate, maximal fat oxidation capacity and serum leptin, free testosterone and osteocalcin in healthy adult men PMID: 29130706
  41. The CRISPR/Cas9 system was able to edit the expression of AR and restrain the growth of androgen-dependent prostate cancer cells in vitro, suggesting the potential of the CRISPR/Cas9 system in future cancer therapy. PMID: 29257308
  42. A new mechanism for complete androgen insensitivity syndrome (CAIS). A deep intronic pseudoexon-activating mutation in the intron between exons 6 and 7 of AR, detected in two siblings with CAIS, leads to aberrant splicing of the AR mRNA and insufficient AR protein production. PMID: 27609317
  43. In the current work, we have confirmed that the lead androgen receptor DBD inhibitor indeed directly interacts with the androgen receptor DBD and tested that substance across multiple clinically relevant castration-resistant prostate cancer cell lines PMID: 28775145
  44. Androgen receptor CAG repeat polymorphism is not associated with insulin resistance and type 2 diabetes in Sri Lankan males. PMID: 29202793
  45. AR gene CAG repeat polymorphisms are associated with the increased risk of mild endometriosis PMID: 28915409
  46. ARE full sites generate a reliable transcriptional outcome in AR positive cells, despite their low genome-wide abundance. In contrast, the transcriptional influence of ARE half sites can be modulated by cooperating factors. PMID: 27623747
  47. Targeting the Malat1/AR-v7 axis via Malat1-siRNA or ASC-J9 can be developed as a new therapy to better suppress enzalutamide-resistant prostate cancer progression. PMID: 28528814
  48. High circulating AR-V7 levels predicted resistance to abiraterone and enzalutamide in castration-resistant prostate cancer. PMID: 28818355
  49. Results identified the N-terminal region of AR-V7 (splice variants) that interacts with the diffuse B-cell lymphoma homology (DH) domain of Vav3 which increases its expression in castration-resistant prostate cancer (CRPC). PMID: 28811363
  50. The single nucleotide polymorphism G1733A of the androgen receptor gene is significantly associated with recurrent spontaneous abortions in Mexican patients. PMID: 28707146
  51. AR can directly regulate cellular growth and control signaling pathways in castration-resistant prostate cancer cells. PMID: 27641228
  52. Report increased androgen receptor gene copy number and protein expression in treatment-naive prostate cancer. PMID: 28052297
  53. This review focuses on AR variants signaling pathways and their role in resistance to castration and prostate cancer progression. [review] PMID: 28945566
  54. Here the authors show that the AF-1 domain of AR is bound by the cochaperone Bag-1L. PMID: 28826504
  55. based on this assay, AR-LBD mutations such as F877L and T878A are not common contributors to de novo or acquired resistance to apalutamide PMID: 28633425
  56. Here, the authors show that action of activated AR partitions into fractions that are controlled preferentially by different coregulators. In a 452-AR-target gene panel, each of 18 clinically relevant coregulators mediates androgen-responsiveness of 0-57% genes and acts as a coactivator or corepressor in a gene-specific manner. PMID: 28826481
  57. Mechanistically, AR modulated cytokine CXCL5 expression by altering AKT --> NF-kappaB signaling, and interruption of AKT --> NF-kappaB --> CXCL5 signaling using either specific inhibitors or siRNA suppressed AR-enhanced EC recruitment and AR-EC-promoted RCC progression. PMID: 27848972
  58. At 12 moths, men with 22-23 CAG presented with a statistically significantly lower sperm concentration than those with other CAG numbers following testicular germ cell cancer treatment PMID: 27873769
  59. Data show that androgen receptor variant AR-V9 (AR-V9) may play a significant role in promoting androgen-independent growth of castration-resistant prostate cancer (CRPC) cells, and that AR-V9 mRNA expression in CRPC metastases was predictive of primary resistance to abiraterone acetate. PMID: 28473535
  60. Alterations in the androgen receptor are associated with endocrine treatment outcomes in castration-resistance prostate cancer. PMID: 28104311
  61. there is association between the AR CAG repeat polymorphism and ovarian cancer risk (Meta-Analysis). PMID: 28250337
  62. Prostate cancer cells expressing an S273A mutant of CHIP have attenuated AR degradation upon 2-ME treatment compared with cells expressing wild-type CHIP, supporting the idea that CHIP phosphorylation by Aurora A activates its E3 ligase activity for the AR PMID: 28536143
  63. CDK2 contributes to S81-AR phosphorylation and transactivation while CDK4 was not shown to be involved in this process. PMID: 29157894
  64. Data show that androgen receptor (AR) status was significantly associated with brain metastasis in epithelial ovarian cancer (EOC). PMID: 28467804
  65. Wild-type and mutant AR physically interact with the APC/CCdh1 complex in a ligand-dependent fashion without being targeted for proteasomal degradation. PMID: 27312068
  66. HER2(+) and triple-negative breast cancer cell lines were treated with AR antagonist plus anti-HER2 mAb trastuzumab or mTOR inhibitor everolimus..AR antagonists synergize with FDA-approved breast cancer therapies such as everolimus and trastuzumab through distinct mechanisms. Treatment combinations are effective in trastuzumab-resistant HER2(+) breast cancer cells in vivo PMID: 28468774
  67. Data indicate that androgen receptor serine515 (AR-515) is a potential prognostic marker and therapeutic target for triple negative breast cancer (TNBC). PMID: 28415597
  68. High concentrations of DINCH urinary metabolites activate human androgen receptors. PMID: 29421333
  69. men carrying shorter (<22) AR CAG repeats have lower HDL-C level and increased risk of hypertension. The androgenic activity may differ due to the polymorphic length of CAG repeats of the AR gene. PMID: 28295444
  70. Inhibition of endogenous miR-30b-3p and miR-30d-5p enhanced AR expression and androgen-independent cell growth. PMID: 27683042
  71. Our analysis, conducted among more than 17,000 women with early-stage breast cancer included in clinical and gene expression analysis, demonstrates that AR positivity is associated with favorable clinical outcome. PMID: 28151718
  72. Study highlights how androgen receptor itself functions is an important step in elucidating the molecular basis for androgen-independent prostate tumors.Translocation of AR to improper gene promoter elements or DNA-binding sites can result in an alteration in gene expression and thus normal prostate function. AR regulation of mir-206 is an important mechanism for prostate tumor progression. [review] PMID: 28598253
  73. The progesterone receptor B (PRB) and androgen Receptor (AR) mRNA levels were highest in tumors. PMID: 29491078
  74. Findings provide the first evidence for a link between the androgen receptor gene and moral judgment and highlight the role of androgens in moral foundations. PMID: 28324702
  75. Patients with circulating tumor cells that had AR-V7 protein in the cellular nuclei were very likely to survive longer on taxane-based chemotherapy. PMID: 27979426
  76. the deregulation of androgen receptor (AR) expression is a driver of chromatin relaxation and that AR/androgen-regulated bromodomain-containing proteins (BRDs) mediate this effect. PMID: 28591577
  77. Differential expression of miR-34b and androgen receptor are associated with prostate cancer aggressiveness in African-Americans and Caucasians. PMID: 28039468
  78. AR and AR-related gene expression could be utilized to predict the prognosis of metastatic breast cancer. PMID: 28060723
  79. Studies indicate that androgen receptor (AR) signaling differentially regulates proliferation of prostatic epithelia cells through mechanisms involving stromal/epithelial interactions. PMID: 27611945
  80. These findings suggest that calpain and AR-V7 may serve as important biomarkers in the treatment of castration-resistant prostate cancer , and targeting calpain and AR-V7 may provide a new approach in overcoming docetaxel-resistance. PMID: 28498452
  81. With respect to competitiveness, whereas the number of CAG repeats was not associated with the choice to compete, a lower number of CAG repeats was related to greater confidence in those who chose to compete, but this effect was attributable to the polymorphism's effect on actual performance. PMID: 27702564
  82. DNAH8 has a role in androgen receptor activity and prostate cancer progression PMID: 27363033
  83. A novel nonsense mutation in androgen receptor confers resistance to CYP17A1 inhibitor treatment in prostate cancer. PMID: 28036278
  84. Social selection favors offspring prone to the development of androgenetic alopecia due to the length of the CAG repeat located in the androgen receptor gene on the X chromosome. PMID: 29254307
  85. We demonstrated that the AR-miR-1 axis negatively regulates the novel oncogenic factor, TCF7. Dysregulation of TCF7 promoted a survival advantage and resistance to androgen deprivation, suggesting its therapeutic potential for castration-resistant prostate cancer. PMID: 28220803
  86. Study show that phosphorylation of AR at Ser-578 is strongly associated with PKC expression. Also, the expression of pARS578 in hormone-naive prostate cancer was observed to be a negative prognostic marker associated with decreased survival from biochemical relapse and decreased disease-specific survival. These results suggest that PKC driven AR phosphorylation may promote prostate cancer progression. PMID: 27902483
  87. We identified a molecular signature of secreted proteins associated with AA ultraresponsiveness and sustained AR/GR signaling upon AA resistance in intermediate or minimal responders. These data will inform development of noninvasive biomarkers predicting AA response and suggest that further inhibition along the AR/GR signaling axis may be effective only in AA-resistant patients who are intermediate or minimal responders PMID: 27993966
  88. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner in prostate tumor cells. PMID: 28038451
  89. Castration resistant prostate cancer progression is facilitated via Src-induced sensitization of AR to intracrine androgen levels, resulting in the engagement of canonical and non-canonical ARBS-dependent gene signatures. PMID: 28055971
  90. A large proportion of metastatic endometrial cancer lesions express AR, which may be a potential target in these patients PMID: 27384477
  91. Report a significant survival benefit in lung adenocarcinoma patients with positive expression of one of the investigated hormonal receptors: androgen receptor, estrogen receptor-alpha or progesterone receptor. PMID: 27690341
  92. AR activation correlates with Cisplatin resistance presumably via modulating NF-kappaB activity in bladder cancer cells PMID: 27322140
  93. PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity. PMID: 27835608
  94. Despite increased androgen synthesis inhibition, we demonstrate that tumor AR axis remains important in disease progression. We highlight that abiraterone metabolism and pharmacokinetics may play a role in resistance. PMID: 27683182
  95. Immunohistochemical analyses of tissue microarrays from benign human tissues confirmed expression of AR in endothelial cells from several androgen-regulated and non-androgen-regulated human organs. PMID: 27679502
  96. Data show that phosphorylated forms of nucleophosmin 1 (NPM1) interact with androgen receptor (AR) in nucleoplasm. PMID: 26993766
  97. We show AR expressed in cancer-associated fibroblasts (CAFs) contributes to the tumor-promoting abilities that CAFs exert on epithelial prostate cancer cells. Further, we found that decreased AR expression in CAFs is also associated with an increase in stem cell marker gene expression in prostate cancer epithelial cells. PMID: 28264911
  98. Within an institutional cohort, the RNA ISH assay identified AR-V7 within FFPE tissue and may have prognostic value in metastatic castration-sensitive prostate cancer. These preliminary findings warrant further study in larger cohorts. PMID: 27440270
  99. increases hematogenous metastasis yet decreases lymphatic metastasis of renal cell carcinoma through differential regulation of VEGF-A vs. VEGF-C via miR-185-5p PMID: 29030639
  100. Data show that enzalutamide resistance was accompanied by increased androgen receptor (AR) mRNA and protein expression as well as AR gene amplification. PMID: 27486973

Show More

Hide All

Involvement in disease Androgen insensitivity syndrome (AIS); Spinal and bulbar muscular atrophy X-linked 1 (SMAX1); Androgen insensitivity, partial (PAIS)
Subcellular Location Nucleus, Cytoplasm
Protein Families Nuclear hormone receptor family, NR3 subfamily
Tissue Specificity Isoform 2 is mainly expressed in heart and skeletal muscle (PubMed:15634333). Isoform 3 is expressed by basal and stromal cells of prostate (at protein level) (PubMed:19244107).
Database Links

HGNC: 644

OMIM: 300068

KEGG: hsa:367

STRING: 9606.ENSP00000363822

UniGene: Hs.76704

Most popular with customers

  Tel: 301-363-4651
  Distributors Worldwide


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1